The so-called PEACE-1 trial is an ongoing Phase III trial among men diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-sensitive, de nove, earky, mCSPC, metastatic, PEACE-1, results, rPFS, trial | 7 Comments »
The second day of the APCCC here in Basel ran for 10 hours and encompassed a total of six sessions, as follows: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, APCCC, bone, castration-resistant, castration-sensitive, future, metastatic, side effects | Leave a comment »
According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval of apalutamide (Eleada) in the treatment of men with metastatic, castration-sensitive prostate cancer (mCSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, castration-sensitive, mCSPC, metastatic, trial, TRITON | 3 Comments »
According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-sensitive, Erleada, hormone-sensitive, mCSPC, metastatic, mHSPC, outcome, TITAN, trial | Leave a comment »
Late yesterday the US Food and Drug Administration announced the approval of abiraterone acetate (Zytiga) + prednisone for the treatment of men with “high-risk, castration-sensitive”, metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-sensitive, hormone-sensitive, Zytiga | Leave a comment »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK